Highlights

  • EBR Systems (ASX:EBR) surpassed 100 commercial WiSE CRT System implants as adoption across US hospitals continues expanding.
  • CMS selected WiSE for its Transitional Coverage for Emerging Technologies pathway, supporting potential broader Medicare coverage.
  • The company continues expanding hospital relationships, physician Training and commercial infrastructure.
  • Funding requirements and ongoing cash losses remain important considerations as EBR scales operations.

EBR Systems (ASX:EBR) continues advancing the commercial rollout of its WiSE CRT System, with implant volumes, hospital adoption and reimbursement progress becoming central themes for the medical technology company.

The company has reached a key commercial milestone with more than 100 WiSE implants completed following US regulatory approval, while efforts to expand reimbursement access and hospital adoption continue. However, EBR remains in a development and commercial scaling phase, with funding requirements and operating losses still important factors for investors assessing the long-term opportunity.

Commercial Progress

EBR confirmed that cumulative WiSE CRT System implants reached 117 following the Limited Market Release period that began after FDA approval in April 2025.

During the June 2026 quarter, the company completed 46 patient implants, following 41 implants in the previous quarter. The company has now trained 90 physicians across 30 hospital sites, including additional centres added during the period.

The milestone reflects continued progress in building a US commercial network for the wireless left-ventricle pacing technology, which is designed for heart failure patients requiring cardiac resynchronisation therapy.

Hospital adoption remains a key measure of commercial progress, as purchasing agreements must translate into trained physicians, active centres and recurring procedure volumes.

Reimbursement Progress

Reimbursement remains a major Factor in EBR’s growth strategy.

The Centers for Medicare & Medicaid Services initiated a National Coverage Determination process through its Transitional Coverage for Emerging Technologies (TCET) pathway in June 2026, with WiSE selected as the first device under the program.

A national Medicare coverage decision could provide a more consistent reimbursement framework and support broader adoption across healthcare providers.

The company’s reimbursement progress also includes existing payment support for eligible procedures, while international opportunities continue developing. In Australia, the WiSE system has received regulatory review support that may assist future market access.

Financial Performance

EBR remains focused on commercial expansion while operating at a loss as it invests in manufacturing, sales infrastructure and physician training.

For the six months ended 30 June 2026, the company reported net product sales of approximately US$5.0 million, including around US$2.6 million during the second quarter.

The company reported a net loss of approximately US$34.5 million for the half year, reflecting continued Investment required to scale operations.

Operating cash outflow was approximately US$37.4 million during the period, while the accumulated Deficit increased as the company continued investing ahead of broader commercial adoption.

EBR maintained cash and marketable securities of approximately US$87 million to US$90 million at the end of June 2026, before additional proceeds from its Capital raising program.

The company has highlighted ongoing funding requirements, including future obligations and the need to maintain sufficient Liquidity as it progresses towards larger-scale commercial activity.

Growth Drivers

The expansion of EBR’s US hospital network remains the primary near-term growth driver.

During the period, the company secured purchasing agreements with several major healthcare networks, expanding access to potential implant centres. These agreements represent important steps in the commercial adoption process by allowing individual hospitals to begin ordering the system.

The broader opportunity is linked to the need for improved treatment Options for patients who may not receive adequate results from traditional cardiac resynchronisation therapy approaches.

Artificial intelligence and digital healthcare trends are not direct drivers of the device itself, but broader healthcare technology investment continues supporting interest in innovative medical solutions.

Operational Developments

EBR continues investing in Manufacturing capability and operational infrastructure to support future demand.

The company is transitioning manufacturing activities to a new Santa Clara facility, with plans to close its previous Sunnyvale location.

EBR has also continued strengthening its Balance Sheet through capital raising initiatives designed to provide additional funding flexibility during its commercial expansion phase.

The company previously disclosed a serious adverse event involving two patients during post-implant echocardiograms at one site. EBR stated that the events were associated with the imaging procedure rather than the device itself and continues engaging with regulatory authorities regarding the assessment.

Investor Focus

Key areas investors will monitor include:

  • Growth in quarterly implant volumes and expansion of active hospital sites.
  • Progress through the CMS Transitional Coverage for Emerging Technologies pathway.
  • Conversion of purchasing agreements into completed procedures and recurring utilisation.
  • Manufacturing expansion and operating cost management.
  • Funding requirements and progress towards reducing reliance on external capital.

Risks

EBR remains a pre-profit medical technology company with significant investment requirements.

The company’s Revenue base remains small compared with operating expenses, meaning continued access to capital remains important while commercial adoption develops.

Hospital adoption may take time, as agreements require implementation, physician training and ongoing procedural activity before contributing meaningful revenue.

Regulatory and clinical risks also remain relevant. Any future safety concerns, regulatory delays or slower-than-expected reimbursement progress could affect adoption timelines.

The company also faces execution risks associated with scaling manufacturing, expanding commercial operations and managing cash requirements.

Outlook

EBR Systems enters the next phase of 2026 with measurable commercial progress, including more than 100 WiSE implants, a growing physician network and expanding hospital relationships.

The company’s longer-term opportunity depends on converting early adoption into broader procedure volumes and securing wider reimbursement access through initiatives such as the CMS coverage pathway.

While the commercial milestones demonstrate progress, investors will continue assessing the balance between growth investment, funding requirements and the pace at which revenue can scale.

For investors following ASX healthcare and medical technology stocks, EBR remains a company where commercial execution, reimbursement outcomes and financial discipline will shape the next stage of its development.